ASCO 2023 | Interim results from ARCADIA trial: cabozantinib plus durvalumab in advanced urothelial carcinoma

Patrizia Giannatempo, MD, Foundation IRCCS National Cancer Institute, Milan, Italy, discusses the Phase II ARCADIA (NCT03824691) trial investigating the combination of cabozantinib, a multitargeted receptor tyrosine kinase inhibitor, and durvalumab, a checkpoint inhibitor, in patients with advanced urothelial carcinoma (UC) and non-UC histology (VHs). The study aimed to assess overall survival (OS) as the primary endpoint, along with secondary endpoints such as safety, objective response rate (ORR), duration of response (DoR), and progression-free survival (PFS). The first interim analysis included the first 63 patients, with a median follow-up of 23.5 months. The combination therapy demonstrated promising activity, with an ORR of 39.7% and a disease control rate of 69%. Median PFS was 7.6 months, and median OS was 11.6 months. The treatment showed a manageable safety profile, with most adverse events being of low grade. Further evaluation of this combination is warranted in ongoing clinical trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.